The Drugs Controller General of India (DCGI) is likely to approve Phase III trial data of Covaxin on Tuesday, sources said.

The Subject Expert Committee (SEC) under the drug regulator reviewed Covaxin's Phase III trial data on Tuesday and the vaccine's efficacy has turned out to be 77.8 per cent.